Genetic risk score
To build a GRS for sorafenib, we estimated the genetic profiles of
patients depending on frequencies of genotypes and alleles of examined
gene polymorphisms. For each SNP, a score of 0 was defined for
homozygous non-responder alleles, 1 for heterozygous responder and
non-responder alleles, and 2 for two homozygous responder
alleles.22-24 The response-increasing alleles were
attributed based on their greater frequency in response subjects
according to the literature data for angiogenesis-related
genes9-11,25 and by data obtained in the present study
for ADME-related genes. For each subject, a combined GRS was calculated
as the sum of these response-increasing alleles; the score was 0-10 for
5 variants.